Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial - Scorecard - MDSpire
Advertisement
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial
Clinical Scorecard: Reduced Systemic Absorption with High-Dose Delgocitinib Cream in Adults with Severe Chronic Hand Eczema: Findings from the DELTA 2 Phase 3 Randomized, Double-Blind, Vehicle-Controlled Trial
At a Glance
Category
Detail
Condition
Chronic Hand Eczema (CHE)
Key Mechanisms
Topical pan-Janus kinase inhibitor with minimal systemic absorption.
Target Population
Adults with moderate to severe Chronic Hand Eczema.
Care Setting
Clinical trial setting.
Key Highlights
Delgocitinib cream 20 mg/g shows minimal systemic exposure even under maximal use conditions.
Significant improvement in efficacy endpoints compared to cream vehicle.
Favorable safety profile similar to cream vehicle in adults with severe CHE.
Guideline-Based Recommendations
Diagnosis
Chronic Hand Eczema is defined as hand eczema persisting for longer than 3 months or recurring at least twice within 1 year.
Management
Delgocitinib cream is indicated for adults with moderate to severe CHE for whom topical corticosteroids are inadequate.
Monitoring & Follow-up
Monitor for systemic exposure and potential adverse events during treatment.
Risks
Topical corticosteroids may lead to dermal atrophy and tachyphylaxis with prolonged use.
Patient & Prescribing Data
Adults with moderate to severe Chronic Hand Eczema.
Delgocitinib cream is effective with minimal systemic absorption, reducing the risk of systemic side effects.
Clinical Best Practices
Utilize delgocitinib cream as a second-line treatment when topical corticosteroids are ineffective.
Assess patient response and systemic exposure regularly during treatment.
by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield
